In a dose escalation phase 1/1b trial of AM0010 in 14 different cancer types rIL-10 activated immune cells (CD8+ T cells), increased pro-inflammatory cytokines, decreased TGFβ, and induced partial and complete clinical responses [58]. The gene discussed is TGFB1; the disease is cancer.